AmerisourceBergen Corporation ABC posted adjusted earnings of $1.33 per share in the fourth quarter of fiscal 2017, beating the Zacks Consensus Estimate by a penny and increasing 2.3% on a year-over-year basis. The upside was primarily driven by strong growth in the company’s Consulting Services, MWI Animal Health and World Courier businesses.
Revenues improved almost 4.2% to $39.1 billion in the reported quarter. However, revenues lagged the Zacks Consensus Estimate of $40.1 billion.
FY17 at a Glance
In fiscal 2017, AmerisourceBergen reported adjusted earnings of $5.88 per share, up 4.6% year over year. Revenues increased 4.3% to $153.1 billion on a year-over-year basis.
Major Highlights
In the fourth quarter, AmerisourceBergen collaborated with Blue Cross Blue Shield Association, Pfizer PFE, Prime Therapeutics and Walgreens Boots Alliance WBA to combat the opioid abuse crisis in the United States. The companies aim to expand the availability of safe medication disposal kiosks to Walgreens stores, particularly in areas where the opioid epidemic has hit communities.
In the reported quarter, AmerisourceBergen initiated product shipments to Walgreens’ retail pharmacies.
Added to this, AmerisourceBergen launched an online, interactive cell and gene therapy resource that provides insights for patients facing challenges pertaining to treatment procedures.
AmerisourceBergen Corporation (Holding Co) Price and Consensus
AmerisourceBergen Corporation (Holding Co) Price and Consensus | AmerisourceBergen Corporation (Holding Co) Quote
Segmental Analysis
Pharmaceutical Distribution Segment: The Pharmaceutical Distribution Services segment historically included AmerisourceBergen Drug Corporation (“ABDC”) and AmerisourceBergen Specialty Group (“ABSG”). In the reported quarter, revenues at the segment were $37.7 billion, up 3.9% on a year-over-year basis. ABDC revenues were up 4.2%, primarily on the back of solid organic sales growth.
The ABSG unit performed impressively during the quarter, with revenues rising 10.3% year over year. The increase can be attributed to strong oncology product sales and solid performance by the third-party logistics business.
Other Segment: This segment includes AmerisourceBergen Consulting Services (“ABCS”), World Courier and MWI Veterinary Supply. Revenues at the segment came in at $1.5 billion, up 12.2% on a year-over-year basis.
Margin Details
In the fourth quarter, AmerisourceBergen registered gross profit of $1.1 billion, up 4.4% on a year-over-year basis. As a percentage of revenues, gross margin in the fourth quarter was 2.8%, flat year over year.
Operating expenses in the fourth quarter were $626 million, reflecting an increase of 6.8% year over year. As a percentage of revenues, operating margin expanded 4 basis points (bps) to 1.6% in the quarter.
Guidance
AmerisourceBergen issued guidance for fiscal 2018. The company expects adjusted earnings per share for fiscal 2018 in the band of $5.90 to $6.15. Revenue growth for the fiscal is expected in the range of 7% to 9%.
AmerisourceBergen expects adjusted operating expenses to increase in the range of 4% to 6%, while adjusted operating income growth is estimated in the band of 3% to 5%;
Meanwhile, operating income growth at the pharmaceutical distribution services segment is anticipated in the range of 3% to 5%.
Peer Release
PetMed Express, Inc.’s PETS adjusted earnings per share of 43 cents in the second quarter of fiscal 2018 were up 79.2% from the year-ago quarter. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment